23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Phathom Pharmaceuticals, Inc. › 2025-2026

Phathom Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Phathom Pharmaceuticals, Inc.’s Form 8-K, filed May 21, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 185Asset managers, any item
  • 1,047Fund votes
  • May 19, 2026Meeting date

Results at a glance

Meeting of May 19, 2026: 5 items on Phathom Pharmaceuticals, Inc.’s Form 8-K, filed May 21, 2026: 3 elected · 1 approved · 1 passed (calculated).

Dissent

Notable dissent: 1 director (12.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Phathom Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Phathom Pharmaceuticals, Inc.

These tallies are Phathom Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 21, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Phathom Pharmaceuticals, Inc. — official shareholder meeting results, meeting held May 19, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Steven Basta 42,656,800---- 4,490,78117,487,652 90%Elected—
Elect Director: Theodore R. Schroeder 42,578,532---- 4,569,04917,487,652 90%Elected—
Elect Director: Mark Stenhouse 41,249,990---- 5,897,59117,487,652 87%Elected—
2. Ratification of Independent Registered Public Accounting Firm 64,482,75749,661102,815 ---- 99.9%Approved—
3. Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers 44,449,7612,532,145165,675 --17,487,652 95%Passed (calculated)—

Source: Phathom Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 21, 2026 — read the filing on EDGAR.

How asset managers voted at the Phathom Pharmaceuticals, Inc. 2025-2026 meeting

185 asset managers disclosed a vote on at least one Phathom Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Steven Basta

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 42,656,800WITHHELD: 4,490,781
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Steven Basta”): 42,656,800 for, 4,490,781 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,712,4840 60For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed00 0727,425Withhold
Fidelity598,1590 03,858For
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES00 0285,271Withhold
Simplify Exchange Traded Funds262,3860 00For
Equitable246,6600 00For
Brighthouse158,1970 015,814Mixed
Ivy Variable Insurance Portfolios00 0136,785Withhold
Securian Funds Trust00 0116,572Withhold
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I00 053,501Withhold
AMG Funds IV38,2680 00For
State Street36,7570 029For
Russell Investments35,2710 00For
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI30,5760 00For
ProShares00 027,435Withhold

Fund voting reports, all 53 managers: 8,860,069 for, 1,434,235 withheld, 6 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Catalys Pacific, LLC1,493,8540 00For

Institutional-manager reports, all 1 managers: 1,493,854 for.

Elect Director: Mark Stenhouse

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 41,249,990WITHHELD: 5,897,591
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mark Stenhouse”): 41,249,990 for, 5,897,591 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 8,307,410 for, 1,986,893 withheld, 7 abstained.

FORWITHHOLD
FOR: 8,307,410ABSTAIN: 7WITHHOLD: 1,986,893
Largest asset managers voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,711,2260 71,256For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed00 0727,425Withhold
Fidelity598,1590 03,858For
Charles Schwab00 0408,473Withhold
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES00 0285,271Withhold
Simplify Exchange Traded Funds262,3860 00For
Equitable216,8800 029,780Mixed
Brighthouse158,1970 015,814Mixed
Ivy Variable Insurance Portfolios00 0136,785Withhold
Securian Funds Trust00 0116,572Withhold
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I00 053,501Withhold
AMG Funds IV38,2680 00For
State Street36,7570 029For
Russell Investments00 035,271Withhold
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI00 030,576Withhold
ProShares00 027,435Withhold

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Theodore R. Schroeder

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 42,578,532WITHHELD: 4,569,049
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Schroeder

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Theodore R. Schroeder”): 42,578,532 for, 4,569,049 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 8,830,289 for, 1,464,015 withheld, 6 abstained.

FORWITHHOLD
FOR: 8,830,289ABSTAIN: 6WITHHOLD: 1,464,015
Largest asset managers voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Sch” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,712,4840 60For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed00 0727,425Withhold
Fidelity598,1590 03,858For
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES00 0285,271Withhold
Simplify Exchange Traded Funds262,3860 00For
Equitable216,8800 029,780Mixed
Brighthouse158,1970 015,814Mixed
Ivy Variable Insurance Portfolios00 0136,785Withhold
Securian Funds Trust00 0116,572Withhold
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I00 053,501Withhold
AMG Funds IV38,2680 00For
State Street36,7570 029For
Russell Investments35,2710 00For
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI30,5760 00For
ProShares00 027,435Withhold

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 13 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 44,449,761AGAINST: 2,532,145

Prior year: 73.8% for (June 3, 2025 meeting) ▲ 20.8 pts

Details: description as filed, official tally, votes by 184 asset managers

Description as filed by funds: To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").

Phathom Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers”): 44,449,761 for, 2,532,145 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,690,714282,617 00Mixed
Vanguard1,711,2301,259 00For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed727,4250 00For
Fidelity337,930264,087 00Mixed
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES285,2710 00For
Simplify Exchange Traded Funds262,3860 00For
Equitable246,6600 00For
Brighthouse174,0110 00For
Ivy Variable Insurance Portfolios136,7850 00For
Securian Funds Trust116,5720 00For
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs056,141 00Against
JPMorgan54,5040 00For
ETFis Series Trust I53,5010 00For
AMG Funds IV038,268 00Against
State Street36,7851 00For
Russell Investments035,271 00Against
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI030,576 00Against
ProShares27,4350 00For

Fund voting reports, all 53 managers: 9,538,792 for, 744,572 against, 10,946 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 147 asset managers voting on “To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.12,466,4890 00For
Medicxi Ventures Management (Jersey) Ltd7,464,5720 00For
Invesco3,773,700343,805 00Mixed
Carlyle Group Inc.3,496,8080 00For
NEA Management Company, LLC1,960,1690 00For
Ensign Peak Advisors, Inc1,807,5800 00For
683 Capital Management, LLC1,679,0830 00For
WASATCH ADVISORS LP1,337,9610 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,066,4800 00For
BlackRock892,27998,591 00Mixed
FRANKLIN ADVISERS INC787,6840 00For
PERCEPTIVE ADVISORS LLC694,5220 00For
GW&K Investment Management, LLC0686,873 00Against
EcoR1 Capital, LLC625,0000 00For
Catalio Capital Management, LP586,0410 00For
State Street563,410894 00For
GEODE CAPITAL MANAGEMENT, LLC486,6780 00For
Charles Schwab408,4800 00For
Woodline Partners LP362,1210 00For
Avidity Partners Management LP0249,390 00Against
Northern Trust211,3574,296 00For
MARSHALL WACE, LLP0182,890 00Against
AMERIPRISE FINANCIAL INC0164,581 00Against
MELLON INVESTMENTS Corp120,5750 00For
T. Rowe Price104,9610 00For

Institutional-manager reports, all 147 managers: 41,788,694 for, 2,143,324 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 64,482,757AGAINST: 49,661

Prior year: 99.7% for (June 3, 2025 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Phathom Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 64,482,757 for, 49,661 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2026:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 10,288,364 for, 5,946 abstained.

FOR
FOR: 10,288,364ABSTAIN: 5,946
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,712,4900 00For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed727,4250 00For
Fidelity602,0170 00For
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES285,2710 00For
Simplify Exchange Traded Funds262,3860 00For
Equitable246,6600 00For
Brighthouse174,0110 00For
Ivy Variable Insurance Portfolios136,7850 00For
Securian Funds Trust116,5720 00For
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I53,5010 00For
AMG Funds IV38,2680 00For
State Street36,7860 00For
Russell Investments35,2710 00For
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI30,5760 00For
ProShares27,4350 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Largest Phathom Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 79,442,367 shares outstanding at the time of that meeting.

Fund voting reports: top Phathom Pharmaceuticals, Inc. shareholders by shares voted on “To approve the compensation of the named executive officers on a non-binding advisory basis…”, 2025-2026
#Asset manager % of shares outstanding
1Invesco 3.74%
2Vanguard 2.16%
3WASATCH FUNDS TRUST 1.66%
4Waddell & Reed 0.92%
5Fidelity 0.76%
6Charles Schwab 0.51%
7BlackRock 0.45%
8Jackson National 0.40%
9FRANKLIN STRATEGIC SERIES 0.36%
10Simplify Exchange Traded Funds 0.33%
Institutional-manager reports: top Phathom Pharmaceuticals, Inc. shareholders by shares voted on “To approve the compensation of the named executive officers on a non-binding advisory basis…”, 2025-2026
#Asset manager % of shares outstanding
1Frazier Life Sciences Management, L.P. 15.69%
2Medicxi Ventures Management (Jersey) Ltd 9.40%
3Invesco 5.18%
4Carlyle Group Inc. 4.40%
5NEA Management Company, LLC 2.47%
6Ensign Peak Advisors, Inc 2.28%
7683 Capital Management, LLC 2.11%
8WASATCH ADVISORS LP 1.68%
9NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST 1.34%
10BlackRock 1.25%

Reported Phathom Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Phathom Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Invesco4,322,060 5.44%Form 13F, quarter ended March 31, 2026
BlackRock4,061,996 5.11%Form 13F, quarter ended March 31, 2026
Millennium Management4,022,909 5.06%Form 13F, quarter ended March 31, 2026
Vanguard Group3,177,211 4.00%Form 13F, quarter ended March 31, 2026
State Street1,386,890 1.75%Form 13F, quarter ended March 31, 2026
Geode Capital1,328,045 1.67%Form 13F, quarter ended March 31, 2026
Franklin Templeton994,504 1.25%Form 13F, quarter ended March 31, 2026
Citadel Advisors918,158 1.16%Form 13F, quarter ended March 31, 2026
Goldman Sachs626,196 0.79%Form 13F, quarter ended March 31, 2026
Two Sigma482,136 0.61%Form 13F, quarter ended March 31, 2026

Percentages above are of 79,442,367 shares outstanding, as reported by Phathom Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Phathom Pharmaceuticals, Inc.'s shareholder meeting held May 19, 2026, in the 2025-2026 proxy season, 185 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,047 separate fund positions. On the most widely held item on that ballot — To approve the compensation of the named executive officers on a non-binding advisory basis… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Phathom Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 21, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Phathom Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Phathom Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Phathom Pharmaceuticals (PHAT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/phathom-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.